7th International Lung Cancer Seminar

Tinos Island GREECE

4 - 6 September 2020
Cultural Foundation of Tinos
PRELIMINARY PROGRAM

Friday September 4, 2020

13.30-14.30 Registration opens

14.30-15.00 Lecture I
Chairpersons: V. Iordanoglou, C. Marinou

Smoking and lung cancer epidemiology
K. Poulopoulos

15.00-15.30 Lecture II
Chairpersons: V. Polychronopoulos, I. Davlopoulos

E-cigarette and heated tobacco: A new old story
D. Kyroussis

15.30–16.00 Lecture III
Chairpersons: I. Andreou, I. Kostara

Imaging evaluation of response in NSCLC
Th. Pipikos

16.00-16.30 Lecture IV
Chairpersons: L. Zellos, M. Doris

Minimal thoracic surgery-maximum efficacy. What new in 2020
C. Iliadis

16.30-17.00 Coffee break

17.00-18.00 Round Table I: THYMOMA
Chairpersons: A. Petounis, D. Malios, P. Skarlos

Histological classification and prognosis
S. Papadopoulos

Surgery
L. Toufexian

Radiotherapy
I. Georgakopoulos

Novel treatments
E. Res
18.00-18.30 Satellite Lecture I
Chairpersons: P. Kosmidis, A. Gaga

kras G12G: Identifying new driving mutation in NSCLC
I. Boukovinas

18.30-19.00 Lecture V
Chairpersons: C. Christodoulou, A. Kotsakis

Mesothelioma: Immunotherapy. When? Any progress?
S. Demiri

19.00-19.30 Satellite Lecture II
Chairpersons: P. Kosmidis, D. Stamatopoulos

Thromboembolic events in NSCLC. Is there a real threat?
I. Boukovinas

19.30-20.00 Workshop I: Artificial Intelligence: here to stay?
Chairpersons: A. Nikolaidi, N. Kentepozidis, N. Desses

- Genomics: Predict treatment?: G. Lypas
- Radiomics: Replace biopsy?: N. Papanikolaou

20.00-20.30 Controversies I: EARLY LUNG CANCER IN SPECIFIC GROUPS
Chairpersons: E. Samantas, M. Piperi, F. Stavridi

Surgery: N. Baltagiannis

Radiotherapy: S. Kosmidis

20.30-21.00 Opening Ceremony
Welcome addresses
I. Boukovinas (President of HESMO)
G. Fountzilas (President of HeCOG)
P. Kosmidis (President of the Seminar)
C. Iliadis (President of the Seminar)

HONORARY LECTURE

21.00 Welcome Reception
Saturday September 5, 2020

09.00-09.30 Lecture VII
Chairpersons: D. Pectasides, K. Ploiarchopoulou, A. Koumarianou

Tumor heterogeneity and resistance to treatment
S. Lambropoulos

09.30 – 10.30 Round Table II: RESISTANCE TO IMMUNE CHECK POINT INHIBITORS
Chairpersons: E. Samantas, C. Marinou, N. Mitsimponas

Intrinsic to relation to driver mutation
A. Laskarakis

Intrinsic in relation to TMB
A. Stribakos

Acquired resistance
E. Saloustros

10.30 – 11.30 Round Table III: IMMUNOTHERAPY: NEW AVENUES
Chairpersons: G. Fountzilas, S. Murray, C. Margari

Adjuvant: H. Linardou

Neoadjuvant: I. Mountzios

Maintenance: I. Athanasiadis

11.30-12.00 Satellite Lecture III SPONSORED BY BRISTOL MYERS SQUIBB
Chairpersons: A. Psyri, C. Andreadis

The Dual Inhibition of Check point Inhibitors in 1st line NSCLC treatment
H. Linardou

12.00-12.30 Coffee Break

12.30-13.00 Lecture VIII
Chairpersons: F. Matsouka, V. Polychronopoulos

Immunotherapy in small cell lung cancer. Any hope?
A. Nikolaidi

13.00-13.30 Controversies II: CAN WE TAILOR THE DURATION OF IMMUNOTHERAPY?
Chairpersons: A. Psyri, C. Bakogiannis, D. Tryfonopoulos
Up to 2 years: G. Lainakis
Indefinitely: A. Kotsakis

13.30-14.30 Round Table III: 2nd LINE TREATMENT FOLLOWING IMMUNOTHERAPY
Chairpersons: V. Georgoulias, A. Laskarakis, K. Ploiarchopoulou

During relapse: Z. Saridaki
Following 2 years of treatment and relapse: V. Barbounis
Hyperprogressive disease: N. Kentepozidis

14.30-15.30 Light Lunch

15.30-16.00 Workshop II: METASTASIS
Chairpersons: P. Papakostas, D. Tryfonopoulos, S. Demiri

- Oligometastasis. What to do?: H. Galani
- Oligoprogression. What to do?: C. Panopoulos

16.00-16.30 Lecture IX
Chairpersons: L. Florentin, S. Murray, S. Livanos

Genotyping: From academic research to clinical practice: G. Nasioulas

16.30-17.30 Round Table IV: FIRST LINE FOR ONCOGENE ADDICTED LUNG CANCER
Chairpersons: G. Koumakis, V. Ramfidis, C. Antonopoulos

Key factors that determine the selection of first line EGFR TKI: F. Stavridi

Key factors that determine the selection of first line ALK inhibitors: C. Andreadis

17.30-18.00 Satellite Lecture IV
Chairpersons: D. Bafaloukos, G. Rigakos, J. Mountzios

Non small cell lung cancer: The importance of BRAF mutation: M. Tsiatas

18.00-18.30 Coffee Break

18.30-19.00 Satellite Lectures V
Chairpersons: P. Papakostas, A. Petounis

Therapeutic approaches beyond chemotherapy in the adjuvant setting of NSCL: A. Koumarianou
New perspectives and challenges in the treatment of SCLC: Th. Tegos

19.00-19.30 Workshop III: CARCINOID LUNG TUMORS
Chairpersons: C. Iliadis, N. Chatzinikolaou, E. Res

- Surgery: state of the art: L. Zellos
- Targeted treatment: A. Koumarianou

19.30-20.00 Satellite Lecture VI
Chairpersons: H. Linardou, A. Lalousis, S. Saridaki

Developing next generation inhibitors in the management of ALK+ NSCLC; focusing on 3rd generation: A. Christopoulou
**Sunday September 6, 2020**

10.00-11.00  **Round Table V: COMBINED TREATMENT IN STAGE III NSCLC**  
Chairpersons: E. Zachariadis, C. Tsigaridas, I. Georgakopoulos

- Concurrent chemoradiotherapy: V. Rapti
- Concurrent Immunoradiotherapy: M. Theochari
- Radiation combined with targeted treatments: M. Piperi

11.00-11.30  **Workshop IV: Brain metastasis**  
Chairpersons: F. Matsouka, N. Mitsimponas, N. Desses

- Brain metastasis: are all the same?: G. Rigakos
- Radiotherapy: when? How?: P. Skarlos

11.30-13.00  **Round Table VI: ASCO 2020**  
Chairpersons: C. Bakogiannis, H. Goniotaki, A. Lalousis

- Small cell lung cancer: V. Ramfidis
- NSCLC: Chemotherapy: TBA
- NSCLC: Targeted therapy: C. Margari
- NSCLC: Immunotherapy: P. Papadopoulos

13.00-13.30  **Closing Remarks**